Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs).

Tissue microarrays have become a valuable tool for high-throughput analysis using immunohistochemical labeling. However, the large majority of biochemical studies are carried out in cell lines to further characterize candidate biomarkers or therapeutic targets with subsequent studies in animals or using primary tissues. Thus, cell line-based microarrays could be a useful screening tool in some situations. Here, we constructed a cell microarray (CMA) containing a panel of 40 pancreatic cancer cell lines available from American Type Culture Collection in addition to those locally available at Johns Hopkins. As proof of principle, we performed immunocytochemical labeling of an epithelial cell adhesion molecule (Ep-CAM), a molecule generally expressed in the epithelium, on this pancreatic cancer CMA. In addition, selected molecules that have been previously shown to be differentially expressed in pancreatic cancer in the literature were validated. For example, we observed strong labeling of CA19-9 antigen, a prognostic and predictive marker for pancreatic cancer. We also carried out a bioinformatics analysis of a literature curated catalog of pancreatic cancer biomarkers developed previously by our group and identified two candidate biomarkers, HLA class I and transmembrane protease, serine 4 (TMPRSS4), and examined their expression in the cell lines represented on the pancreatic cancer CMAs. Our results demonstrate the utility of CMAs as a useful resource for rapid screening of molecules of interest and suggest that CMAs can become a universal standard platform in cancer research.

[1]  D. Simeone,et al.  Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. , 2012, Journal of proteome research.

[2]  Z. Rasheed,et al.  Biological and clinical relevance of stem cells in pancreatic adenocarcinoma , 2012, Journal of gastroenterology and hepatology.

[3]  H. Mellstedt,et al.  Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. , 2012, Cancer treatment reviews.

[4]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[5]  J. Neefjes,et al.  Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.

[6]  P. Andrews,et al.  Identification of blood‐protein carriers of the CA 19‐9 antigen and characterization of prevalence in pancreatic diseases , 2011, Proteomics.

[7]  P. Went,et al.  EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis , 2011, Journal of Clinical Pathology.

[8]  Shan-Rong Shi,et al.  Antigen Retrieval Immunohistochemistry , 2011, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  Kumaran Kandasamy,et al.  SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome , 2010, Cancer biology & therapy.

[10]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[11]  C. Drake Prostate cancer as a model for tumour immunotherapy , 2010, Nature Reviews Immunology.

[12]  Semi Kim,et al.  TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. , 2010, Carcinogenesis.

[13]  K. Ohuchida,et al.  CD44v6 Expression in Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2010, Pancreas.

[14]  S. Hanash,et al.  A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.

[15]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[16]  Young Woo Park,et al.  Role of TMPRSS4 during cancer progression. , 2008, Drug news & perspectives.

[17]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[18]  Wilfried Bardet,et al.  Identification of breast cancer peptide epitopes presented by HLA-A*0201. , 2008, Journal of proteome research.

[19]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[20]  Patrick O. Brown,et al.  Gene Expression Patterns in Pancreatic Tumors, Cells and Tissues , 2007, PloS one.

[21]  F. Pontén,et al.  Antibody-based tissue profiling as a tool for clinical proteomics , 2004, Clinical Proteomics.

[22]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Shastri,et al.  ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. , 2006, Immunity.

[24]  F. Pontén,et al.  Analysis of Protein Expression in Cell Microarrays: A Tool for Antibody-based Proteomics , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  E. Campo,et al.  Paraffin-Embedded Cell Line Microarray (PECLIMA): Development and Validation of a High-Throughput Method for Antigen Profiling of Cell Lines , 2005, Pathobiology.

[26]  Anna M. Heidenblut,et al.  Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions , 2005, Oncogene.

[27]  Q. Duh,et al.  ECM1 and TMPRSS4 Are Diagnostic Markers of Malignant Thyroid Neoplasms and Improve the Accuracy of Fine Needle Aspiration Biopsy , 2005, Annals of surgery.

[28]  V. Speirs,et al.  A novel cell array technique for high-throughput, cell-based analysis , 2005, In Vitro Cellular & Developmental Biology - Animal.

[29]  C. Iacobuzio-Donahue,et al.  Immunohistochemistry and in situ hybridization in pancreatic neoplasia. , 2005, Methods in molecular medicine.

[30]  R. Hruban,et al.  Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays , 2004, Oncogene.

[31]  C. Pilarsky,et al.  Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. , 2004, Neoplasia.

[32]  J. Cameron,et al.  Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. , 2004, The American journal of pathology.

[33]  Alessandro Lugli,et al.  Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.

[34]  Hanno Steen,et al.  Development of human protein reference database as an initial platform for approaching systems biology in humans. , 2003, Genome research.

[35]  Kimberly Walter,et al.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. , 2002, The American journal of pathology.

[36]  J. Akagi,et al.  CA19-9 epitope a possible marker for MUC-1/Y protein. , 2001, International journal of oncology.

[37]  T. Gress,et al.  A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. , 2000, Cancer research.

[38]  P. Coulie,et al.  Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. , 1999, American journal of respiratory and critical care medicine.

[39]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[40]  K. Kinzler,et al.  Identifying markers for pancreatic cancer by gene expression analysis. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  F. Safi,et al.  [Clinical value of the CA 19-9 tumor marker with special reference to the Lewis phenotype]. , 1997, Medizinische Klinik.

[42]  S. Gansauge,et al.  Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. , 1995, Cancer research.

[43]  S. Fox,et al.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.

[44]  C. Mackay,et al.  Expression and modulation of CD44 variant isoforms in humans , 1994, The Journal of cell biology.

[45]  M. Tempero,et al.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.